Recurring Revenue ModelThe subscription-like annual storage fees create a durable, predictable revenue base and high customer lifetime value. This recurring cash inflow supports long-term planning, capacity utilization and makes scaling unit economics easier as customer volumes grow over months to years.

Niche Market LeadershipEstablished specialization in umbilical cord blood storage gives structural competitive advantages: regulatory know-how, trust among families and hospital partnerships. These barriers and domain expertise sustain market share and pricing power over the medium term.

Revenue Growth MomentumMaterial revenue expansion indicates successful customer acquisition and service uptake, supporting scale economies. If sustained, this growth can improve gross margins, spread fixed costs and provide a platform for reinvestment into product offerings and partnership expansion.

Bears Say

High Financial LeverageElevated leverage increases fixed interest obligations and reduces financial flexibility, limiting the firm's ability to fund capex or weather cyclical slowdowns. Over months, this raises refinancing and solvency risk, particularly if cash generation does not strengthen.

Persistent UnprofitabilityNegative ROE and recurring net losses constrain retained earnings and limit internal funding for growth. Sustained unprofitability pressures equity value, deters investment, and forces reliance on external capital which can dilute shareholders or increase debt.

Weak Cash Flow ConversionInability to convert income into cash undermines the company's capacity to service debt, invest in capacity or fund working capital from operations. Over a multi-month horizon this may necessitate costly financing, constrain growth initiatives, and elevate liquidity risk.

V3V FAQ

What was VITA 34 AG’s price range in the past 12 months?

VITA 34 AG lowest stock price was €3.70 and its highest was €7.65 in the past 12 months.

What is VITA 34 AG’s market cap?

VITA 34 AG’s market cap is €92.39M.

When is VITA 34 AG’s upcoming earnings report date?

VITA 34 AG’s upcoming earnings report date is Mar 31, 2026 which is in 42 days.

How were VITA 34 AG’s earnings last quarter?

VITA 34 AG released its earnings results on Nov 21, 2025. The company reported €0.068 earnings per share for the quarter, beating the consensus estimate of N/A by €0.068.

Is VITA 34 AG overvalued?

According to Wall Street analysts VITA 34 AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does VITA 34 AG pay dividends?

VITA 34 AG pays a Annually dividend of €0.16 which represents an annual dividend yield of N/A. See more information on VITA 34 AG dividends here

What is VITA 34 AG’s EPS estimate?

VITA 34 AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does VITA 34 AG have?

VITA 34 AG has 17,640,104 shares outstanding.

What happened to VITA 34 AG’s price movement after its last earnings report?

VITA 34 AG reported an EPS of €0.068 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of VITA 34 AG?

Currently, no hedge funds are holding shares in DE:V3V

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

VITA 34 Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-50.39%

Trailing 12-Months

Asset Growth

-0.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

VITA 34 AG

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.